Evidence map›Paper›PMID 32272898›Full record

ArticleBMC gastroenterology2020

Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis.

Chih-Wen Lin, Yaw-Sen Chen, Gin-Ho Lo, Yao-Chun Hsu, Chia-Chang Hsu, Tsung-Chin Wu, Jen-Hao Yeh, Pojen Hsiao, Pei-Min Hsieh, Hung-Yu Lin and 2 more

Open access · goldAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 3 pooled it
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Transarterial chemoembolization with 125 I seed insertion for unresectable hepatocellular carcinoma: a meta‑analysis.Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Chih-Wen LinDivision of Gastroenterology and Hepatology, E-Da Dachang Hospital, I-Shou University, Kaohsiung, Taiwan.
Yaw-Sen ChenSchool of Medicine, College of Medicine, I-Shou University, 82445, No. 1, Yida Road, Jiaosu Village, Yanchao District, Kaohsiung, Taiwan.
Gin-Ho LoDivision of Gastroenterology and Hepatology, E-Da Dachang Hospital, I-Shou University, Kaohsiung, Taiwan.
Yao-Chun HsuDivision of Gastroenterology and Hepatology, Department of Medicine, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
Chia-Chang HsuHealth Examination Center, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
Tsung-Chin WuDivision of Gastroenterology and Hepatology, E-Da Dachang Hospital, I-Shou University, Kaohsiung, Taiwan.
Jen-Hao YehDivision of Gastroenterology and Hepatology, E-Da Dachang Hospital, I-Shou University, Kaohsiung, Taiwan.
Pojen HsiaoDivision of Gastroenterology and Hepatology, E-Da Dachang Hospital, I-Shou University, Kaohsiung, Taiwan.
Pei-Min HsiehDepartment of Surgery, E-Da Hospital, I-Shou University, No. 1, Yida Road, Jiaosu Village, Yanchao District, Kaohsiung, 82445, Taiwan.
Hung-Yu LinSchool of Medicine, College of Medicine, I-Shou University, 82445, No. 1, Yida Road, Jiaosu Village, Yanchao District, Kaohsiung, Taiwan.
Chih-Wen ShuSchool of Medicine, College of Medicine, I-Shou University, 82445, No. 1, Yida Road, Jiaosu Village, Yanchao District, Kaohsiung, Taiwan.
Chao-Ming HungSchool of Medicine, College of Medicine, I-Shou University, 82445, No. 1, Yida Road, Jiaosu Village, Yanchao District, Kaohsiung, Taiwan. ed101968@edah.org.tw.
I-Shou University · TWChina Medical University Hospital · TWE-Da Hospital · TW

Funding

Ministry of Science and Technology, Taiwan 108-2314-B-214-006-MY2
6 · The paper itself

Abstract

backgroundPatients with Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma (HCC) are recommended to undergo transcatheter arterial chemoembolization (TACE). However, TACE in combination with radiofrequency ablation (RFA) is not inferior to surgical resection (SR), and the benefits of surgical resection (SR) for BCLC stage B HCC remain unclear. Hence, this study aims to compare the impact of SR, TACE+RFA, and TACE on analyzing overall survival (OS) in BCLC stage B HCC.

methodsOverall, 428 HCC patients were included in BCLC stage B, and their clinical data and OS were recorded. OS was analyzed by the Kaplan-Meier method and Cox regression analysis.

resultsOne hundred forty (32.7%) patients received SR, 57 (13.3%) received TACE+RFA, and 231 (53.9%) received TACE. The OS was significantly higher in the SR group than that in the TACE+RFA group [hazard ratio (HR): 1.78; 95% confidence incidence (CI): 1.15-2.75, p = 0.009]. The OS was significantly higher in the SR group than that in the TACE group (HR: 3.17; 95% CI: 2.31-4.36, p < 0.0001). Moreover, the OS was significantly higher in the TACE+RFA group than that in the TACE group (HR: 1.82; 95% CI: 1.21-2.74, p = 0.004). The cumulative OS rates at 1, 3 and 5 years in the SR, TACE+RFA, and TACE groups were 89.2, 69.4 and 61.2%, 86.0, 57.9 and 38.2%, and 69.5, 37.0 and 15.2%, respectively. After propensity score matching, the SR group still had a higher OS than those of the TACE+RFA and TACE groups. The TACE+RFA group had a higher OS than that of the TACE group.

conclusionThe SR group had higher OS than the TACE+RFA and TACE groups in BCLC stage B HCC. Furthermore, the TACE+RFA group had higher OS than the TACE group.

Indexed as

HepatectomyRadiofrequency AblationAdultAgedAged, 80 and overAntineoplastic AgentsCarcinoma, HepatocellularChemoembolization, TherapeuticCombined Modality TherapyFemaleFollow-Up StudiesHumansLiver NeoplasmsLogistic ModelsMaleMiddle AgedAntineoplastic AgentsBarcelona clinic liver Cancer stage BHepatocellular carcinomaOverall survivalRadiofrequency ablationSurgical resectionTranscatheter arterial chemoembolization

Identifiers

PMID32272898
PMCPMC7147026
OpenAlexW3015267176

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.